Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-10.96% US089482100.472
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 43.62 mill |
EPS: | -0.500 |
P/E: | -0.940 |
Earnings Date: | Mar 27, 2024 |
SharesOutstanding: | 92.43 mill |
Avg Daily Volume: | 1.483 mill |
RATING 2024-03-28 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Buy | |
Return On Asset: | Sell | |
DE: | Strong Sell | |
P/E: | Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.940 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.16x |
Company: PE -0.940 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
US089482100.145 (-69.30%) US08948210-0.327 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
US08948210 0.400 - 0.544 ( +/- 15.26%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-28 | Rehnquist Janet | Buy | 0 | |
2023-09-13 | Narido Richard Clavano | Buy | 0 | |
2023-08-30 | Gorovitz Aaron | Buy | 35 000 | Common Stock, par value $0.001 per share |
2023-08-30 | Hurvitz Chaim | Buy | 70 000 | Common Stock, par value $0.001 per share |
2023-08-23 | Javitt Jonathan C | Buy | 100 000 | Common Stock |
INSIDER POWER |
---|
-0.66 |
Last 86 transactions |
Buy: 35 919 718 | Sell: 5 833 033 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | US089482100.472 (-10.96% ) |
Volume | 2.53 mill |
Avg. Vol. | 1.483 mill |
% of Avg. Vol | 170.93 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.